Skip to main content

448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study

Publication ,  Conference
Stadtmauer, E; Karlin, L; Weisel, K; Gatt, ME; Kansagra, A; Monohan, G; Yee, A; Rockow-Magnone, S; Cordero, J; Hoffman, D; Bueno, O; Wu, K ...
Published in: Regular and Young Investigator Award Abstracts
November 2021

Duke Scholars

Published In

Regular and Young Investigator Award Abstracts

DOI

Publication Date

November 2021

Publisher

BMJ Publishing Group Ltd

Conference Name

SITC 36th Anniversary Annual Meeting (SITC 2021) Abstracts

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stadtmauer, E., Karlin, L., Weisel, K., Gatt, M. E., Kansagra, A., Monohan, G., … Gasparetto, C. (2021). 448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study. In Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd. https://doi.org/10.1136/jitc-2021-sitc2021.448
Stadtmauer, Edward, Lionel Karlin, Katja Weisel, Moshe Etzion Gatt, Ankit Kansagra, Gregory Monohan, Andrew Yee, et al. “448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study.” In Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd, 2021. https://doi.org/10.1136/jitc-2021-sitc2021.448.
Stadtmauer E, Karlin L, Weisel K, Gatt ME, Kansagra A, Monohan G, et al. 448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study. In: Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2021.
Stadtmauer, Edward, et al. “448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study.” Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, 2021. Crossref, doi:10.1136/jitc-2021-sitc2021.448.
Stadtmauer E, Karlin L, Weisel K, Gatt ME, Kansagra A, Monohan G, Yee A, Rockow-Magnone S, Cordero J, Hoffman D, Bueno O, Wu K, Gasparetto C. 448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study. Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2021.

Published In

Regular and Young Investigator Award Abstracts

DOI

Publication Date

November 2021

Publisher

BMJ Publishing Group Ltd

Conference Name

SITC 36th Anniversary Annual Meeting (SITC 2021) Abstracts

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology